loading
Schlusskurs vom Vortag:
$2.35
Offen:
$2.34
24-Stunden-Volumen:
3.06M
Relative Volume:
1.51
Marktkapitalisierung:
$175.80M
Einnahmen:
$32.31M
Nettoeinkommen (Verlust:
$-237.09M
KGV:
-0.7708
EPS:
-2.88
Netto-Cashflow:
$-219.11M
1W Leistung:
+12.69%
1M Leistung:
+35.37%
6M Leistung:
+69.47%
1J Leistung:
-55.95%
1-Tages-Spanne:
Value
$2.15
$2.385
1-Wochen-Bereich:
Value
$1.935
$2.55
52-Wochen-Spanne:
Value
$0.9101
$6.05

Editas Medicine Inc Stock (EDIT) Company Profile

Name
Firmenname
Editas Medicine Inc
Name
Telefon
617-401-9000
Name
Adresse
11 HURLEY ST., CAMBRIDGE, MA
Name
Mitarbeiter
226
Name
Twitter
@editasmed
Name
Nächster Verdiensttermin
2025-05-02
Name
Neueste SEC-Einreichungen
Name
EDIT's Discussions on Twitter

Vergleichen Sie EDIT mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
EDIT
Editas Medicine Inc
2.22 175.80M 32.31M -237.09M -219.11M -2.88
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
440.87 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
509.72 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
309.70 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.15 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
247.08 28.51B 3.81B -644.79M -669.77M -6.24

Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-28 Eingeleitet H.C. Wainwright Buy
2024-12-16 Herabstufung JP Morgan Neutral → Underweight
2024-12-13 Herabstufung Chardan Capital Markets Buy → Neutral
2024-12-13 Herabstufung Stifel Buy → Hold
2024-12-13 Herabstufung Truist Buy → Hold
2024-12-11 Herabstufung Wells Fargo Overweight → Equal Weight
2024-11-25 Herabstufung BofA Securities Buy → Underperform
2024-11-06 Hochstufung Evercore ISI In-line → Outperform
2024-11-04 Herabstufung Raymond James Outperform → Mkt Perform
2024-08-08 Hochstufung BofA Securities Neutral → Buy
2024-05-09 Hochstufung Morgan Stanley Underweight → Equal-Weight
2023-10-24 Hochstufung Citigroup Neutral → Buy
2023-10-18 Hochstufung JP Morgan Underweight → Neutral
2023-10-17 Herabstufung Cantor Fitzgerald Overweight → Neutral
2023-09-29 Hochstufung Stifel Hold → Buy
2023-06-12 Hochstufung Raymond James Mkt Perform → Outperform
2023-02-01 Eingeleitet Cantor Fitzgerald Overweight
2022-12-13 Eingeleitet Citigroup Neutral
2022-12-06 Fortgesetzt Credit Suisse Neutral
2022-11-18 Herabstufung Credit Suisse Outperform → Neutral
2022-11-18 Herabstufung Oppenheimer Outperform → Perform
2022-09-29 Eingeleitet BofA Securities Neutral
2021-10-19 Eingeleitet SVB Leerink Mkt Perform
2021-09-24 Eingeleitet Stifel Hold
2021-09-10 Hochstufung Oppenheimer Perform → Outperform
2021-08-09 Hochstufung Truist Hold → Buy
2021-08-05 Hochstufung Evercore ISI Underperform → Outperform
2021-06-04 Fortgesetzt Robert W. Baird Outperform
2021-05-04 Eingeleitet RBC Capital Mkts Sector Perform
2021-04-16 Eingeleitet Goldman Sell
2021-03-22 Eingeleitet Credit Suisse Outperform
2021-03-01 Herabstufung Barclays Overweight → Equal Weight
2021-02-26 Herabstufung Truist Buy → Hold
2021-01-19 Herabstufung Morgan Stanley Equal-Weight → Underweight
2021-01-07 Herabstufung Raymond James Outperform → Mkt Perform
2020-12-10 Hochstufung Wells Fargo Equal Weight → Overweight
2020-11-03 Eingeleitet Robert W. Baird Underperform
2020-06-18 Fortgesetzt SunTrust Buy
2020-02-21 Eingeleitet Wells Fargo Equal Weight
2019-04-12 Eingeleitet Evercore ISI Outperform
2018-10-10 Eingeleitet Guggenheim Neutral
2018-09-21 Eingeleitet Raymond James Outperform
2018-05-15 Bestätigt Chardan Capital Markets Buy
2018-02-13 Eingeleitet CLSA Underperform
2018-01-23 Hochstufung SunTrust Hold → Buy
2017-07-14 Eingeleitet SunTrust Hold
2017-03-28 Eingeleitet Chardan Capital Markets Buy
2016-08-10 Hochstufung Jefferies Hold → Buy
2016-06-02 Eingeleitet Jefferies Hold
2016-02-29 Eingeleitet JMP Securities Mkt Outperform
2016-02-29 Eingeleitet JP Morgan Neutral
2016-02-29 Eingeleitet Morgan Stanley Equal-Weight
Alle ansehen

Editas Medicine Inc Aktie (EDIT) Neueste Nachrichten

pulisher
Jun 19, 2025

Cancer Gene Therapy Market Set to Soar: Breakthrough - openPR.com

Jun 19, 2025
pulisher
Jun 18, 2025

From Now to 2032: Unpacking the Genome Editing Market's - openPR.com

Jun 18, 2025
pulisher
Jun 17, 2025

Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - AOL.com

Jun 17, 2025
pulisher
Jun 17, 2025

Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - The Motley Fool

Jun 17, 2025
pulisher
Jun 17, 2025

Analysts Set Editas Medicine, Inc. (NASDAQ:EDIT) Price Target at $5.36 - MarketBeat

Jun 17, 2025
pulisher
Jun 14, 2025

Editas Medicine, Inc. (NASDAQ:EDIT) Position Trimmed by Bank of America Corp DE - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Analysts Offer Predictions for Editas Medicine FY2026 Earnings - MarketBeat

Jun 14, 2025
pulisher
Jun 13, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat

Jun 13, 2025
pulisher
Jun 12, 2025

Editas Medicine (EDIT) Unveils Promising Gene Editing Data for B - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Kalkine: Editas Medicine’s In Vivo Gene Editing Progress Unveiled at EHA 2025 with tLNP Approach - Kalkine Media

Jun 12, 2025
pulisher
Jun 12, 2025

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hema - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Editas Medicine Reports 58% HBG1/2 Promoter Editing in Non-Human Primates Using High Efficiency tLNP Delivery Method - Nasdaq

Jun 12, 2025
pulisher
Jun 12, 2025

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June - The Manila Times

Jun 12, 2025
pulisher
Jun 12, 2025

Breakthrough: New Gene Editing Therapy Achieves 58% Success Rate for Sickle Cell Disease Treatment - Stock Titan

Jun 12, 2025
pulisher
Jun 11, 2025

Why Is Editas (EDIT) Up 40% Since Last Earnings Report? - Yahoo Finance

Jun 11, 2025
pulisher
Jun 09, 2025

Ameriprise Financial Inc. Has $289,000 Stake in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat

Jun 09, 2025
pulisher
Jun 08, 2025

Editas Medicine, Inc. (NASDAQ:EDIT) CEO Sells $26,130.24 in Stock - MarketBeat

Jun 08, 2025
pulisher
Jun 07, 2025

Zacks Research Raises Earnings Estimates for Editas Medicine - MarketBeat

Jun 07, 2025
pulisher
Jun 05, 2025

Two Sigma Investments LP Increases Stake in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat

Jun 05, 2025
pulisher
Jun 05, 2025

Millennium Management LLC Has $3.49 Million Stock Position in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat

Jun 05, 2025
pulisher
Jun 04, 2025

Editas Medicine, Inc. (NASDAQ:EDIT) Short Interest Down 21.7% in May - MarketBeat

Jun 04, 2025
pulisher
Jun 02, 2025

editas medicine amends stock plan and increases authorized shares - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

Editas Medicine Stockholders Approve Key Amendments - TipRanks

Jun 02, 2025
pulisher
Jun 02, 2025

editas medicine amends stock plan and increases authorized shares By Investing.com - Investing.com India

Jun 02, 2025
pulisher
Jun 01, 2025

Two Sigma Advisers LP Increases Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat

Jun 01, 2025
pulisher
Jun 01, 2025

Top 5 CRISPR Companies To Invest In (June 2025) - Securities.io

Jun 01, 2025
pulisher
May 31, 2025

Millennium Management LLC Cuts Stock Position in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World

May 31, 2025
pulisher
May 30, 2025

Editas Medicine, Inc. (NASDAQ:EDIT) Shares Purchased by BNP Paribas Financial Markets - Defense World

May 30, 2025
pulisher
May 30, 2025

Northern Trust Corp Has $884,000 Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World

May 30, 2025
pulisher
May 28, 2025

Brokerages Set Editas Medicine, Inc. (NASDAQ:EDIT) Price Target at $5.36 - MarketBeat

May 28, 2025
pulisher
May 28, 2025

Editas Medicine (EDIT) Joins Russell Microcap Index - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit - Seeking Alpha

May 28, 2025
pulisher
May 28, 2025

CRISPR and Cas Genes Market Set to Witness Significant Growth - openPR.com

May 28, 2025
pulisher
May 26, 2025

Editas Medicine’s SWOT analysis: gene editing stock pivots amid challenges By Investing.com - Investing.com Canada

May 26, 2025
pulisher
May 26, 2025

Editas Medicine’s SWOT analysis: gene editing stock pivots amid challenges - Investing.com Australia

May 26, 2025
pulisher
May 25, 2025

1 Stock Down 97% That Could Double, According to Wall Street - AOL.com

May 25, 2025
pulisher
May 24, 2025

Tang Capital Management LLC Purchases Shares of 400,000 Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat

May 24, 2025
pulisher
May 23, 2025

Editas Medicine, Inc. (NASDAQ:EDIT) Given Consensus Rating of “Hold” by Brokerages - Defense World

May 23, 2025
pulisher
May 22, 2025

Jacobs Levy Equity Management Inc. Has $900,000 Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat

May 22, 2025
pulisher
May 21, 2025

Editas Medicine, Inc.'s (NASDAQ:EDIT) Price Is Right But Growth Is Lacking After Shares Rocket 28% - simplywall.st

May 21, 2025

Finanzdaten der Editas Medicine Inc-Aktie (EDIT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Editas Medicine Inc-Aktie (EDIT) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Burkly Linda
EVP, CHIEF SCIENTIFIC OFFICER
Jun 03 '25
Sale
1.72
726
1,252
69,519
O'Neill Gilmore Neil
CEO
Jun 03 '25
Sale
1.72
15,192
26,196
280,282
$21.16
price down icon 1.86%
$34.86
price down icon 0.14%
$20.56
price up icon 1.98%
$102.68
price up icon 3.24%
$106.53
price up icon 2.04%
biotechnology ONC
$247.08
price down icon 2.25%
Kapitalisierung:     |  Volumen (24h):